METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner

METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner

Acquired chemoresistance is a major limiting factor in the clinical treatment of glioblastoma (GBM). However, the mechanism by which GBM acquires therapeutic resistance remains unclear. Here, we aimed to investigate whether METTL3-mediated N6-methyladenosine (m6A) modification contributes to the tem...

Full description

Bibliographic Details
Main Authors: Jia Shi, Gang Chen, Xuchen Dong, Haoran Li, Suwen Li, Shan Cheng, Yongdong Li, Liping Wang, Jiaqi Yuan, Zhiyuan Qian, Jun Dong
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
glioblastoma
temozolomide
resistance
N6-methyladenosine (m 6 A)
METTL3
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.702983/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.702983/full

Similar Items